Neurocrine Biosciences Inc vs Sherwin-Williams Company (The) Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $135.83 (market cap $13.82B), while Sherwin-Williams Company (The) Common Stock trades at $327.77 (market cap $78.78B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 5.7× Neurocrine Biosciences Inc's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SHW | |
|---|---|---|
Market Cap | $13.82B | $78.78B |
Volume | 1,506,669 | 1,403,311 |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $372.60 |
52-Week Low | $123.10 | $293.00 |
Typical Hold Time | 24 Days | — |
Enterprise Value | $13.83B | $92.71B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% over 24 hours amid a broader bearish technical signal, though key moving averages and oscillators show mixed signals. Fundamentally, the company demonstrates robust health with a 97.91% gross profit margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 against a $1.85 expectation. Recent news highlights pipeline advancements, including presentations on Prader-Willi syndrome research and executive appointments, supporting long-term growth narratives beyond its flagship product INGREZZA.
The investment outlook for NBIX is positive, driven by strong analyst consensus with a $204.18 price target and 86.49% buy ratings, reflecting confidence in revenue growth and pipeline diversification. Key risks include execution challenges in commercializing new products and potential pricing pressures on INGREZZA post-2029. Investors should weigh the company's high profitability and cash flow generation against these sector-specific headwinds.
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →